28. Systemic amyloidosis Clinical trials / Disease details


Clinical trials : 267 Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000019732
2015/03/3111/11/2015A randomised trial for the treatment of AL amyloidosis with the high dose Green Tea Extract.A randomised trial for the treatment of AL amyloidosis with the high dose Green Tea Extract. - The high-dose EGCG therapy for AL-Amyloidosis. ligh chain amyloidosisstanderd therapy plus the high dose green tea therapy.
Drug: green tea extract powder
Pharmaceutical formulation: capsules
dose 2400 mg/d p.o. for 6 months every day
standerd therapy
Japanese Red Cross Medical Center, Division of HematologyNULLComplete: follow-up complete20years-oldNot applicableMale and Female60Phase 2Japan
2NCT02015312
(ClinicalTrials.gov)
April 201318/11/2013A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)Light Chain (AL) Amyloidosis;Cardiac InvolvementDrug: Epigallocatechin-3-gallate (EGCG);Drug: PlaceboFlorian MichelGerman Federal Ministry of Education and ResearchCompleted18 YearsN/AAll38Phase 2Germany